Is Eli Lilly Stock A Buy Or A Sell As FDA Plans Meeting To Discuss Alzheimer's Drug?
Investor's Business Daily · 3 days ago
Search results
- 760.00Add to watchlist-11.55 (-1.50%)At close: Fri. May 10, 2024 4:00 PM EDT · Delayed Quote (USD) · Market closed
- Open774.02High777.42Low760.00
- Mkt Cap722.31BP/E (TTM)112.43Div & Yield5.20 & 0.68%
- Prev. Close771.5552 Wk. Low419.8052 Wk. High800.78
What analysts are sayingTop storiesRelated stocks
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity,...
We’re a medicine company turning science into healing to make life better for people around the world. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges.
Current Medicines. For more than 140 years, we have worked tirelessly to develop and deliver trusted medicines and diagnostics that meet real needs. Our growing portfolio of medicines includes treatments in the areas of bone muscle joint, cancer, cardiovascular, diabetes, endocrine, immunology, neurodegeneration, neuroscience, and pain.
Per-Share Earnings, Actuals and Estimates. View the latest Eli Lilly & Co. (LLY) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Mar 31, 2024 · Lilly at a Glance. A heritage 148 years strong: company founded on May 10, 1876. Headquarters located in Indianapolis, Indiana, U.S.A. More than 44,000 employees worldwide. Approximately 10,000 employees engaged in research and development. Clinical research conducted in more than 55 countries.
Six Generations of Caring and Discovery. The Lilly story began more than 140 years ago, when founder Colonel Eli Lilly combined scientific rigor and passion for discovery, with caring for the individuals and communities the company served. Employees honor his legacy by embodying his call to "Take what you find here and make it better and better."
Apr 30, 2024 · INDIANAPOLIS , March 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema.
